Buying pressure lifts Moderna stock higher in today's trading

Traders Union
All News
Financial News
Moderna rises 2.31% today to $48.67

Highlights

Moderna advanced its mRNA Lyme disease vaccine to Phase 2 trials and initiated early-stage hantavirus vaccine research with military partners.
Jefferies Financial Group cut its stake in Moderna by selling over half its shares in the fourth quarter.
Technical outlook shows neutral short-term momentum but a high likelihood of upward movement into the $45.16 to $51.01 range next week, with resistance at $51.01.

Pipeline progress and strategic sales shape sentiment

Moderna has advanced its mRNA Lyme disease vaccine candidate into Phase 2 clinical trials and begun early-stage research on a potential mRNA-based hantavirus vaccine in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University. The company is preparing for an FDA advisory committee meeting on June 18 concerning MFLUSIVA, its mRNA flu vaccine targeting adults aged 50 and above. Additionally, recent disclosures show Jefferies Financial Group Inc. reduced its holdings in Moderna by selling more than half its shares during the fourth quarter.

Anton Kharitonov, expert at Traders Union, sees Moderna's current price action as technically fragile. He notes that despite short-term gains, key indicators like the MACD and ADX highlight weak momentum and bear-dominated intraday trading. Institutional confidence appears shaky following Jefferies' significant share reduction. Vaccine-related news brings speculative optimism but does not counter deep-seated medium-term downward pressure. "The risk of a sustained drop below $45.16 remains elevated unless fundamentals improve dramatically," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, emphasizes the constructive outlook for Moderna. He sees advancement in vaccine pipelines and a potentially positive FDA meeting as key catalysts. The bullish structure remains intact, with all main weekly indicators suggesting further growth. Karapetjanc states, "With upside targets above $51.01 in play, market sentiment and innovation create multiple setups for further appreciation."

Jainam Mehta, market strategist, believes Moderna faces conflicting short-term signals. He notes divergent technical momentum but points out tactical setup potential if price breaks above $51.01. Macro risks remain from recent outflows, so capital protection is key. "Traders should be alert for a volatility squeeze and consider contrarian entries if sentiment further diverges," Mehta advises.

Divergent momentum indicators as sellers keep intraday control

Momentum indicators present mixed signals: the Moving Average Convergence Divergence (MACD) shows a bearish bias on the daily timeframe, and the Average Directional Index (ADX) signals weak trend strength at 14.31. The Relative Strength Index (RSI) is neutral to weak at 45.43. The Stochastic RSI and Commodity Channel Index (CCI) show no overt overbought or oversold pressures, while Bull/Bear Power (BBP) at -0.59 confirms sellers dominate intraday momentum and points to a prevailing oversold condition. Daily price action shows Moderna gained 2.31% ($1.10), with an initial downside gap of about $0.25, and currently trades in the upper part of today’s range as volatility stands at 4.99%. This combination suggests strength toward the session’s highs, yet overall short-term signals remain divergent.

Earlier, analysts noted that while Moderna faced persistent short- and medium-term headwinds, its long-term outlook remained supported by pipeline progress and strategic initiatives. The latest developments underscore a shift toward near-term neutrality, and with volatility elevated, investors should remain alert to a potential breakout above $51.01 or renewed downside pressure below $45.16 in the coming sessions.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.